Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.

Pedro Nazareth Aguiar(Sociedade Brasileira de Oncologia Clínica), Gilberto Lopes(University of Miami), Sarah Simko(University of Miami), Auro del Giglio(Faculdade de Medicina do ABC), Carmélia Maria Noia Barreto(Instituto de Medicina Avançada), Pui San Tan(University of Oxford), Barbara Gutierres Aguiar(Universidade Paulista)
Journal of Clinical Oncology
May 20, 2018
Cited by 7


Related Papers